NASDAQ:EXAC - Nasdaq - US30064E1091
These drug stocks are among the best to buy now because each is making progress in the fight against cancer. Here's what you should know about each.
EXAC – Exactech agrees to revised acquisition by TPG Capital for $49.25/share in cash.
EXAC – Sidoti downgrades to Neutral from Buy. Stock price at the time of this analyst call was $32.00.
EXAC – R.W. Baird reiterates Hold rating, $49 PT. This price target represents a -3.07% downside over the stock’s previous closing price of $50.55.
In a report issued on December 4, Jeff Johnson from Robert W. Baird reiterated a Hold rating on Exactech (NASDAQ: EXAC), with a price target of $49. The company’s shares closed yesterday at $50.55, close to its 52-week high of $50.95. According to TipRanks.com, Johnson is a 4-star analyst with an average return of 8.1%
The post Exactech Receives a Hold from Robert W. Baird appeared first on Analyst Ratings.
The following are the M&A deals, rumors and chatter circulating on Wall Street for Monday, December 4, 2017. Prysmian to Acquire General Cable for $30.00/Share in Cash The...
Gainers Digital Power Corporation (NYSE: DPW) climbed 90.71 percent to close at $3.49 on Monday after climbing 7.65 percent on Friday. Digital Power disclosed that its...
Gabelli analyst Jennie Tsai downgraded Exactech (NASDAQ: EXAC) to Hold today. The company’s shares closed yesterday at $41.85, close to its 52-week high of $42.55. According to TipRanks.com, Tsai is a 4-star analyst with an average return of 19.8% and a 78.8% success rate. Tsai covers the Healthcare sector, focusing on stocks such as Zimmer
The post Gabelli Downgrades Exactech to Hold appeared first on Analyst Ratings.
A deal with a venture capital firm is sending shares soaring.
Mentions: JNJ